Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 10;40:92. doi: 10.1186/s13046-021-01889-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 1 — Expression and clinical significance of ZNF582-AS1 in ccRCC and its subcellular localization in ccRCC cells. a ZNF582-AS1 expression was downregulated in ccRCC tissues (n = 539) compared with in the adjacent normal renal tissues (n = 72) based on TCGA-KIRC data. b Lower ZNF582-AS1 expression was associated with advanced tumor stage (T1-T2 (n = 340), T3-T4 (n = 190)), higher pathological stage (Stage I-II (n = 322), Stage III-IV (n = 205)), distant metastasis (No (n = 440), Yes (n = 80)), and shorter OS (n = 530) and DFS (n = 485) based on TCGA-KIRC data. According to the median cutoff of ZNF582-AS1 expression, patients were divided into two groups for survival analysis. c The heights of the columns in the chart represented the log2-transformed fold changes (ccRCC tissue/ adjacent normal renal tissues) in ZNF582-AS1 expression in 62 patients with ccRCC. d ZNF582-AS1 expression was decreased in ccRCC tissues compared with in the adjacent normal renal tissues based on qRT-PCR results. e ZNF582-AS1 expression was downregulated in advanced tumor stage (T1-T2 (n = 41), T3-T4 (n = 21)) and distant metastatic (No (n = 43), Yes (n = 19)) ccRCC patients. f ZNF582-AS1 expression was generally decreased in ccRCC cells. g Subcellular localization of ZNF582-AS1 in ccRCC cells